De Witte Jan
Known title: President & CEOCIK: 0001776929
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Transaction History
| RMD | ▼ Sell | Open Market | 2,055 | $524K | 11/25/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,073 | $0 | 11/20/2025 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 76 | $19K | 11/11/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 487 | $122K | 11/11/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 2,000 | $487K | 5/20/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,083 | $0 | 11/20/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 796 | $198K | 11/12/2024 | View on chart |
| IART | ▲ Buy | Option Exercise | 9,814 | $0 | 11/1/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 4,262 | $82K | 11/1/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 360 | $79K | 5/15/2024 | View on chart |
| IART | ▲ Buy | Option Exercise | 205 | $0 | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 205 | $7K | 3/11/2024 | View on chart |
| IART | ▲ Buy | Option Exercise | 346 | $0 | 3/10/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 346 | $13K | 3/10/2024 | View on chart |
| IART | ▲ Buy | Option Exercise | 597 | $0 | 1/18/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 597 | $25K | 1/18/2024 | View on chart |
| RMD | ▲ Buy | Grant | 1,768 | $0 | 11/16/2023 | View on chart |
| IART | ▲ Buy | Option Exercise | 9,814 | $0 | 11/1/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 4,262 | $157K | 11/1/2023 | View on chart |
| IART | ▲ Buy | Open Market | 7,792 | $300K | 6/1/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 3,842 | $203K | 3/11/2023 | View on chart |
| IART | ▲ Buy | Grant | 8,848 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Option Exercise | 431 | $0 | 1/18/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 431 | $24K | 1/18/2023 | View on chart |
| RMD | ▲ Buy | Grant | 1,122 | $0 | 11/16/2022 | View on chart |
| RMD | ▲ Buy | Grant | 956 | $0 | 11/18/2021 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 104 | $27K | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released
ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.